An organic heterobicyclic compound that consists of an imidazole ring ortho-fused to a pyridazine ring.
ChEBI ID: 48382
| Member | Definition | Role |
|---|---|---|
| cefozopran | A fourth-generation cephalosporin antibiotic having imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. | cefozopran |
| ponatinib | A benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I). | ponatinib |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (0.94) | 29.6817 |
| 2010's | 334 (62.78) | 24.3611 |
| 2020's | 193 (36.28) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 34 (6.25%) | 5.53% |
| Reviews | 72 (13.24%) | 6.00% |
| Case Studies | 81 (14.89%) | 4.05% |
| Observational | 6 (1.10%) | 0.25% |
| Other | 351 (64.52%) | 84.16% |